GlassScriptPhysician profile
Wayne A Hughes
NPI 1093719601
$195.07
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $161 · 2020: $17.49 · 2022: $16.88.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $27.89 | 2019 | |
| Shire North American Group INC | $27.37 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.99 | 2019 | |
| Genentech USA, INC. | $17.49 | 2020 | |
| Abbvie INC. | $16.88 | 2022 | |
| Amarin Pharma, INC. | $16.19 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $16.15 | 2019 | |
| Boston Scientific Corporation | $15.31 | 2019 | |
| Merck Sharp & Dohme LLC | $12.90 | 2019 | |
| Janssen Pharmaceuticals, INC | $11.27 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $10.63 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wayne Hughes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.